NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Firesid ...

atai Life Sciences N.V. (ATAI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of ...

One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That’s because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results. Thus, these stocks, especially when trading at low prices, have the potential to rapidly increase in value. In such cases, a frenzy can quickly spike the stock, leading to a relatively short-term situation ...

文章核心观点 - 虽然大麻行业在美国已经基本合法化,但还有其他一些替代医疗方式正试图突破监管障碍,如迷幻药物(如精神药物)可能具有医疗应用价值 [1] - 一些新上市的公司开始尝试利用这些化合物的治疗潜力,但这些公司上市后股价迅速飙升后又迅速下跌 [2] - 尽管如此,仍有一些值得关注的精神药物股票,因为多项研究表明LSD、佩洛西宾和氯胺酮在正确剂量下都非常有效地治疗抑郁症 [3] 公司总结 Atai Life Sciences (ATAI) - 是一家研究多种基于精神药物(如氯胺酮、布美布汀和二甲基色胺)的替代疗法的公司 [4][5] - 公司最有前景的药物COMP360正处于III期临床试验阶段,这增加了获得FDA批准的可能性 [5][6] - 公司目前股价较IPO价格低93%,任何一款药物获得好消息都可能迅速提升其价值 [6] Compass Pathways (CMPS) - 是与ATAI合作开发COMP360药物的公司,专注于开发基于佩洛西宾的治疗方案 [8][9] - COMP360在治疗对传统抗抑郁药物无效的抑郁症患者中显示出20%的持续改善和治疗效果 [10][11] Cybin (CYBN) - 专注于开发三种基于佩洛西宾的治疗方案,其中一种已获得FDA突破性治疗地位 [12][13] - 由于公司目前处于研发阶段,过去4个季度一直亏损,投资者可能需要等待公司产生收入 [14]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company's participation: Format: Virtual fireside chat and 1x1 investor meetingsDate and Time: Fireside chat available ...

NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company’s participation: Format: Virtual fireside chat and 1x1 investor meetingsDate and Time: Fireside chat availabl ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours.The Phase 2a part of the study will evaluate the safety, tolerability, subjective effects, and efficacy of a single intravenous (IV) dose of ELE-101 in 6-12 participants with Major Depressive Disorder (MDD). Results are expected in H2 2024.The dose for Phase 2a was selected using preliminary ph ...

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours.The Phase 2a part of the study will evaluate the safety, tolerability, subjective effects, and efficacy of a single intravenous (IV) dose of ELE-101 in 6-12 participants with Major Depressive Disorder (MDD). Results are expected in H2 2024.The dose for Phase 2a was selected using preliminary ph ...